Overview of Dr. Chakraborty
Dr. Rajshekhar Chakraborty is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Arkansas for Medical Sciences (UAMS) College of Medicine and has been in practice 9 years. He is one of 119 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 375 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
161 Fort Washington Ave
New York, NY 10032Fax+1 212-305-6891
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2017 - 2020
University of Arkansas For Medical Sciences College of MedicineClass of 2010- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology
Certifications & Licensure
NY State Medical License 2020 - 2025
OH State Medical License 2017 - 2021
MN State Medical License 2014 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsPrognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy.Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz
Blood. 2024-12-19 - Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.Mohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin
Blood Advances. 2024-12-10 - Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes.Darshi Shah, Francesco Sparano, Catherine Luo, Daniela Krepper, Johannes M Giesinger
Annals of Hematology. 2024-12-07
Abstracts/Posters
- Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsRajshekhar Chakraborty, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
